Pharmacologically active benzimidazole derivatives

Abstract: Novel benzimidazole derivatives (I) are described, of formula wherein A represents n is 0 or 1; m represents 0 or an integer of from 1 to 5 inclusi­ ve, provided that when n is 0, m represents an inte­ ger of from 2 to 5 inclusive; X represents a radical selected from the group consi­ sting of benzyl, fluorobenzyl, alkoxyalkyl and tetra­ hydrofurfuryl; R₁ and R₂ represent each a saturated or unsaturated alkyl radical having of from 1 to 4 carbon atoms or they may form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring selected from the group consisting of pyrrolidine and piperidine, and the corresponding, non-toxic, parma­ ceutically acceptable acid addition salts. The compounds (I) are endowed with an interesting antihista­ minic activity.

Description: The present invention relates to novel benzimidazole derivatives which belong to the class having structure formula: wherein A represents n is 0 or 1; m represents 0 or an integer of from 1 to 5 inclusive, provided that when n is 0, m represents an integer of from 2 to 5 inclusive; X represents a radical selected from the group consisting of benzyl, fluorobenzyl, ethoxyethyl, allyloxyethyl and tetrahydrofurfuryl provided that when X is benzyl and n is 0, m is an integer 3 to 5 inclusive; R₁ and R₂ represent each an alkyl radical having of from 1 to 4 carbon atoms or they may form, together with the adjacent nitrogen atom, an heterocyclic ring; more particularly they may represent an heterocyclic ring selected from the group consisting of pyrrolidine and piperidine, and the corresponding, non-toxic, pharmaceutically acceptable acid addition salts. Benzimidazole derivatives substituted at position 2 with an optionally substituted piperazinylmethylene or homopiperazinylmethylene radical and at position 1 with a substituted ethoxyradical are disclosed in EP-A-0 123 962 and they are endowed with antihistaminic activity. 1-Benzyl-2-(2-dimethylaminoethyl)benzimidazole is cited in the article of Ganellin et al. published on J.Heterocyclic Chem. 3(3), 278-81 (1966) but no pharmacological data are provided therein. The compounds of formula (I) can be easily obtained starting from o-phenylendiamine which is reacted in warm conditions with a suitable acid HOOC-A n -(CH₂) m -N(R)₁R₂, wherin A,n,m,R₁ and R₂ have the avove-mentioned meanings, then treating the so obtained benzimidazole (II), in an alkaline ambient in the presence of a suitable organic solvent, with a suitable halide HalX wherein Hal is preferably a chlorine or bromine atom and X has the above-mentioned meaning. This process may be schematically represented as follows: The reaction a) is carried out at a high temperature, generally at a temperature between 130 and 190°C, while reaction b) is performed at a lower temperature, generally at a temperature between 30 and 70°C, in a suitable aprotic solvent, preferably N,N-dimethylformamide, and in the presence of sodium hydride. Both the intermediate products (II) and the end products (I) may be usefully isolated as non-toxic, suitable, pharmaceutically acceptable acid addition salts, such as, e.g., those obtained with fumaric, maleic and succinic acid. The compounds (I) have demonstrated to possess an interesting antihistaminic activity which is particularly displayed by oral route. The anti-histaminic activity of the compounds of the invention has been evaluated studying either the effect on the mortality induced by histamine, the affinity towards H₁ histaminergic receptors and the effect on the sleeping time interval induced by sodium pentobarbital. The tests were carried out according the following methods. - Effect on the mortality induced by histamine. The method described by Romer D. et al. (Med.Welt, 17 , 791, 1966) was followed and the tests were carried out on male albino guinea pigs (Dunkin-Hartley), weighing 350-450 g, which were kept in cages with a grid floor, on an empty stomach for 24 hrs with water ad libitum. The compounds under examination were dissolved in 0,5% carboxymethylcellolose and orally administered to the animals; 60 minutes later the same animals were intravenously treated with 1,25 mg/kg of histamine dihydrochloride in saline solution. The control animals, to which only the histamine solution had been administered, showed a 100% mortality. It was evaluated ED₅₀ which corresponds to the amount of the compound able to inhibit 50% of the mortality induced by histamine: the estimation of ED₅₀ was carried out applying the 'probit' method (Finney D.J., Statistical methods in biological assay, pg 512, 1957). - Evaluation of the affinity towards H₁ histaminergic receptors. The affinity of the examined compounds towards H₁ histaminergic receptors was evaluated by displacement curves which were obtained at different concentrations, against [³H]Mepyramine in homogenates of rat brain 'in toto' according to the method described by Traub et al. (Proc.Natl.Acad.Sci., 75 , 6290, 1978) with minor modifications. The incubation was performed at 25°C for 15 minutes, in a final volume of 1 ml of 50 mM Na/K phosphate buffer, pH 7.5, in the presence of 2 mM[³H]mepyramine and 1.5 mg of cerebral protein. The test compounds were dissolved in phosphate buffer or dimethylsulfoxide (DMSO), the final concentration of DMSO was 0.5%. Incubation was terminated by filtration through glass fiber GF/B filters pre-soaked with 0.1% polyethylenimine (PEI); the radioactivity trapped by filters was counted by liquid scintillation. - Effect on the sleeping time interval induced by pentobarbital. The tests were carried out on male mice Swiss-Nos (Nossan, Correzzana, Milano) weighing 20-24 g, on an empty stomach for 18 hours, according to the method described by Turner (Screening Methods in Pharmacology, Acad. Press, pg 70,1965). The sleep was induced by intraperitoneal administration of 40 mg/kg sodium pentobarbital. The narcosis start was considered from the moment when the animal, lying on its back, lost its straightening reflex. The narcosis end was considered from the moment when the animal recovered such reflex. The carrier or the compounds under examination were intraperitoneally administered 30 minutes before the pentobarbital administration. The resulting data are expressed as sleeping time increase per cent of the treated animals in comparison with the controls. It was evaluated ED₁₀₀ which represents the concentration of the examined compound necessary to double the sleeping time in comparison to that showed by the control group. - The Letal Dose₅₀ (LD₅₀) was evaluated on mice using Swiss-Nos (Nossan, Correzzana, Milano) mice weighing 18-20 g each. The animals, divided into groups of 10 animals each (5M + 5F), were on an empty stomach for 18 hrs, with water ad libitum, and kept in cages with grid floor. The compounds (I) were dissolved in water or suspended in 0.5% carboxymethylcellulose and intraperitoneally administered to the animals (10 ml/kg). The mortality occurred in the tested animals within the following 6 hours was noted down. At the expiry of the 6th hour, the animals were allowed to eat up to the end of the experimentation which lasted 14 days. During this period all the toxic symptoms and the mortality occuring were noted. The animals which died during the test period and those which were sacrificed at the end of the same, underwent autopsy for a macroscopic examination of their main organs. The experimental data were statistically compared with the X² method and LD₅₀ was extrapolated by the 'probit' method. The data resulting from the tests carried out on some significant compounds of the class (I), evaluated in comparison to the well known antihistaminic compound Terfenadine, are given in the following Table. Compound Histamine mortality ED₅₀ µg/kg os H-receptor 1 binding Ki (nM) sleeping time % increase ED₁₀₀ mg/kg i.p. Acute toxicity LD₅₀ mg/kg i.p. Example 1 4.54 (2.47-8.36) 5.8 IN 250 Example 6 26.0 (7.0-98.1) 6.1 IN >100 Example 9 5.01 (3.10-8.12) 6.1 IN >100 Terfenadine 179.00 (49-652) 283.2 42 (37-50) >100 IN = inactive at the dose of 100 mg/kg i.p. For therapeutic administration, the compounds according to the present invention are used in the form of pharmaceutical preparation which contain said compounds in admixture with pharmaceutically acceptable carriers such as an organic or inorganic solid or liquid excipient suitable for oral or parenteral administration. The compounds of the invention may be contained in these pharmaceutical preparations in the form of free base or in the form of their non-toxic acid addition salts. The inorganic acids which may be employed to prepare these acid addition salts may be, e.g., hydrochloric or sulphuric acid. The organic acids which may be employed are, e.g., maleic, fumaric and succinic acid. The pharmaceutical preparations may be in solid form as capsules, tablets, dragees or in liquid form such as solutions, suspensions or emulsions. If desired, there may be included in the above preparations auxiliary substances such as stabilizing agent and other commonly used additives, or there may be contained other therapeutically active agents suitable to be administered together with the compounds of the invention. The dosage of the compounds will vary from the administration route and will also depend upon the age and condition of the patient. The following Examples are given by way of better illustrating the invention. Example 1 1-(2-Ethoxyethyl)-2-(3-dimethylaminopropyl)benzimidazole Grams 10 4-dimethylaminobutyric acid hydrochloride are heated up till melting together with 6.45 g o-phenylendiamine then it is allowed to cool and 150 ml water are added thereto. The solution is washed with dichloromethane, made alkaline and extracted with dichloromethane. The extracts are collected together, filtered on charcoal, made anhydrous on sodium sulphate and evaporated to dryness. A thick oily reddish residue is obtained, which is triturated with 200 ml diethyl ether to give 5.8 g 2-(3-dimethylaminopropyl)benzimidazole melting at 117-119°C. Grams 6 2-(3-dimethylaminopropyl)benzimidazole in 100 ml N,N-dimethylformamide are treated with 1.8 g 60% sodium hydride, the mixture is warmed up to 60°C and 4 g 2-ethoxyethyl chloride are added thereto. It is maintained at 60°C for 5 hours, then it is poured into water, extracted with diethyl ether and the extracts washed thoroughly with water, filtered on charcoal, made anhydrous on sodium sulphate and evaporated to dryness. The residue is chromatographied on silica gel column eluting with chloroform:methyl alcool (9:1) and it gives 1-(2-ethoxyethyl)-2-(3-dimethylaminopropyl)benzimidazole. Elementary analysis for C₁₆H₂₅N₃O C H N calculated % 69.78 9.15 15.26 found % 70.11 9.30 15.00 Examples 2-13 Operation was carried out according to the above described method and the following compounds were prepared. Ex.2) 1-(2-Ethoxyethyl)-2-(5-dimethylaminovaleryl)benzimidazole, starting from 2-(5-dimethylaminovaleryl)benzimidazole (mp.117-119°C) and 2-ethoxyethyl chloride. Elementary analysis for C₁₈H₂₉N₃O C H N calculated % 71.25 9.63 13.85 found % 69.93 9.74 13.72 Ex.3) 1-(2-Ethoxyethyl)-2-(3-piperidin-1-ylpropyl)benzimidazole as an oil, starting from 2-(3-piperidin-1-ylpropyl)benzimidazole (mp.97-102°C) and 2-ethoxyethyl chloride. Elementary analysis for C₁₉H₂₉N₃O C H N calculated % 72.34 9.27 13.32 found % 72.47 9.35 13.21 Ex.4) 1-(2-Ethoxyethyl)-2-(4-piperidin-1-ylbutyl)benzimidazole as an oil, starting from 2-(4-piperidin-1-ylbutyl)benzimidazole (mp.146-148°C) and 2-ethoxyethyl chloride. Elementary analysis for C₂₀H₃₁N₃O C H N calculated % 72.91 9.48 12.75 found % 73.12 9.54 12.68 Ex.5) 1-Benzyl-2-(3-dimethylaminopropyl)benzimidazole starting from 2-(3-dimethylaminopropyl)benzimidazole and benzyl chloride, mp.121-122°C (as fumarate). Ex.6) 1-(4-fluorobenzyl)-2-(3-dimethylaminopropyl)benzimidazole as an oil, starting from 2-(3-dimethylaminopropyl)benzimidazole and p-fluorobenzyl chloride. Elementary analysis for C₁₉H₂₂N₃F C H N F calculated % 73.28 7.12 13.49 6.10 found % 73.40 7.18 13.35 6.20 Ex.7) 1-Tetrahydrofurfuryl-2-(3-dimethylaminopropyl)benzimidazole as an oil, starting from 2-(3-dimethylaminopropyl)benzimidazole and tetrahydrofurfuryl bromide. Elementary analysis for C₁₇H₂₅N₃O C H N calculated % 71.05 8.77 14.62 found % 70.88 8.90 14.58 Ex.8) 1-(2-Ethoxyethyl)-2-(4-dimethylaminobutyl)benzimidazole as an oil, starting from 2-(4-dimethylaminobutyl)benzimidazole (mp.104-106°C) and 2-ethoxyethyl chloride. Ex.9) 1-(2-Ethoxyethyl)-2-(2-dimethylaminoethyl)benzimidazole starting from 2-(2-dimethylaminoethyl)benzimidazole (mp.128-130°C) and 2-ethoxyethyl chloride. Elementary analysis for C₁₅H₂₃N₃O C H N calculated % 68.93 8.87 16.08 found % 69.15 8.80 15.94 Ex.10) 1-(2-Ethoxyethyl)-2-(3-diethylaminopropyl)benzimidazole as an oil starting from 2-(3-diethylaminopropyl)benzimidazole and 2-ethoxyethyl chloride. Elementary analysis for C₁₈H₂₉N₃O C H N calculated % 71.25 9.63 13.85 found % 71.40 9.60 13.91 Ex.11) 1-(2-Ethoxyethyl)-2-(3-pyrrolidin-1-ylpropyl)benzimidazole as an oil, starting from 2-(3-pyrrolidin-ylpropyl)benzimidazole and 2-ethoxyethyl chloride. Ex.12) 1-(2-Ethoxyethyl)-2-(3-diallylaminopropyl)benzimidazole starting from 2-(3-diallylaminopropyl)benzimidazole and 2-ethoxyethyl chloride. Elementary analysis for C₂₀H₂₉N₃O C H N calculated % 73.36 8.93 12.83 found % 72.94 8.77 12.81 Ex.13) 1-(2-Ethoxyethyl)-2-(1-methyl-2-dimethylaminoethyl)benzimidazole, starting from 2-(1-methyl-2-dimethylaminoethyl)benzimidazole (mp.168-170°C) and 2-ethoxyethyl chloride. Elementary analysis for C₁₆H₂₅N₃O C H N calculated % 69.78 9.15 15.26 found % 69.52 8.98 15.44

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE Benzimidazole derivatives having structure formula: wherein A represents n is 0 or 1; m represents 0 or an integer of from 1 to 5 inclusive, provided that when n is 0, m represents an integer of from 2 to 5 inclusive; X represents a radical selected from the group consisting of benzyl, fluorobenzyl, ethoxyethyl, allyloxyethyl and tetrahydrofurfuryl provided that when X is benzyl and n is 0, m is an integer 3 to 5 inclusive; R₁ and ₂ represent each an alkyl radical having of from 1 to 4 carbon atoms or they may form, together with the adjacent nitrogen atom, an heterocyclic ring selected from the group consisting of pyrrolidine and piperidine, and, additionally, the following compound: 1-(2-ethoxyethyl)-2-(3-diallylaminopropyl)benzimidazole, and their corresponding non-toxic, pharmaceutically acceptable, acid addition salts. Benzimidazole derivatives according to claim 1, wherein R₁ and R₂ each represent the methyl radical. Benzimidazole derivatives according to claim 1, wherein R₁ and R₂ together with the adjacent nitrogen atom form a pyrrolidine ring. A compound according to claim 1, which is 1-(2-Ethoxyethyl)-2-(3-dimethylaminopropyl)benzimidazole. A compound according to claim 1, which is 1-Benzyl-2-(3-dimethylaminopropyl)benzimidazole. A compound according to claim 1, which is 1-(4-Fluorobenzyl)-2-(3-dimethylaminopropyl)benzimidazole. A compound according to claim 1, which is 1-(2-Ethoxyethyl)-2-(2-dimethylaminoethyl)benzimidazole. A pharmaceutical composition which comprises a therapeutically active amount of one or more compounds according to claims 1 to 7 in admixture with suitable pharmaceutically acceptable diluents. Claims for the following Contracting State : ES, GR A process for the preparation of benzimidazole derivatives of the structure formula: wherein A represents n is 0 or 1 m represents 0 or an integer of from 1 to 5 inclusive, provided that when n is 0, m represents an integer of from 2 to 5 inclusive; X represents a radical selected from the group consisting of benzyl, fluorobenzyl, ethoxyethyl, allyloxyethyl and tetrahydrofurfuryl provided that when X is benzyl and n is 0, m is an integer 3 to 5 inclusive; R₁ and R₂ represent each an alkyl radical having of from 1 to 4 carbon atoms or they may form, together with the adjacent nitrogen atom, an heterocyclic ring selected from the group consisting of pyrrolidine and piperidine, and, additionally, the following compound: 1-(2-ethoxyethyl)-2-(3-diallylaminopropyl)benzimidazole, and their corresponding non-toxic, pharmaceutically acceptable acid addition salts, characterized in that o-phenylendiamine is made to react with a suitable acid HOOC-An-(CH₂) m -N(R₁)R₂ wherein A, n, m, R₁ and R₂ have the above-mentioned meaning, that the obtained benzimidazole derivative is reacted in alkaline ambient in the presence of a suitable solvent with an halide Hal X wherein Hal is an halogen atom and X has the above-mentioned meaning or o-phenylendiamine is made to react with HOOC-(CH₂)₃-N(CH₂-CH=CH₂ )₂ and that the obtained benzimidazole derivative is reacted in alkaline ambient in the presence of a suitable solvent with an halide Hal-CH₂-CH₂OCH₂CH₃ wherein Hal is an halogen atom and that, optionally the obtained derivatives are transformed into their corresponding non-toxic, pharmaceutically acceptable acid addition salts. A process according to claim 1, characterized in that benzimidazole derivatives in which R₁ and R₂ represent methyl radical, are prepared. A process according to claim 1, characterized in that benzimidazole derivatives in which R₁ and R₂ together with the adjacent nitrogen atom form a pyrrolidine ring, are prepared. A process according to claim 2, wherein the benzimidazole derivative obtained is 1-(2-ethoxyethyl)-2-(3-dimethylaminopropyl)benzimidazole. A process according to claim 2, wherein the benzimidazole derivative obtained is 1-benzyl-2-(3-dimethylaminopropyl)benzimidazole. A process according to claim 2, wherein the benzimidazole derivative obtained is 1-(4-fluorobenzyl)-2-(3-dimethylaminopropyl)benzimidazole. A process according to claim 2, wherein the benzimidazole derivative obtained is 1-(2-ethoxyethyl)-2-(2-dimethylaminoethyl)benzimidazole. Process according to any one of the previous claims characterized in that the obtained benzimidazole derivative is used as an active principle for phamaceutical compositions having antihistaminic activity.

Inventors: GIANI ROBERTO, PARINI ETTORE, TONON GIANCARLO, GIANI, ROBERTO, PARINI, ETTORE, TONON, GIANCARLO
Applicants: DOMPE FARMACEUTICI SPA, DOMPE' FARMACEUTICI S.P.A.
Application year: 1989
Main classification: C07D235
IPC codes: A61K31, C07D405, C07D235, A61P43